Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Alizée Jenvrin"'
Autor:
Julien Magne, Alizée Jenvrin, Adrien Chauchet, Olivier Casasnovas, Anne Donzel, Laurence Jego, Bernard Aral, Julien Guy, Nathalie Nadal, Dewi Vernerey, Patrick Callier, Francine Garnache-Ottou, Christophe Ferrand
Publikováno v:
Experimental Hematology & Oncology, Vol 7, Iss 1, Pp 1-6 (2018)
Abstract Background Expression of SRY [sex-determining region Y]-box11 (SOX11) is specific to mantle cell lymphoma (MCL) and contributes, in conjunction with immunoglobulin variable heavy chain gene mutation status, to the identification of two forms
Externí odkaz:
https://doaj.org/article/60a803136ecc40979713345b9c4f2169
Autor:
Laure Philippe, Adam Ceroi, Elodie Bôle-Richard, Alizée Jenvrin, Sabeha Biichle, Sophie Perrin, Samuel Limat, Francis Bonnefoy, Eric Deconinck, Philippe Saas, Francine Garnache-Ottou, Fanny Angelot-Delettre
Publikováno v:
Haematologica, Vol 102, Iss 11 (2017)
Blastic plasmacytoid dendritic cell neoplasm is an aggressive hematologic malignancy with a poor prognosis. No consensus regarding optimal treatment modalities is currently available. Targeting the nuclear factor-kappa B pathway is considered a promi
Externí odkaz:
https://doaj.org/article/06f07cfd6ea84c7b824101eccd0b827d
Autor:
Adrien Chauchet, Julien Magne, Francine Garnache-Ottou, Christophe Ferrand, Alizée Jenvrin, Olivier Casasnovas, Anne Donzel, Dewi Vernerey, Nathalie Nadal, Julien Guy, Bernard Aral, Laurence Jego, P. Callier
Publikováno v:
Experimental Hematology & Oncology, Vol 7, Iss 1, Pp 1-6 (2018)
Experimental Hematology & Oncology
Experimental Hematology & Oncology, 2018, 7 (1), pp.5. 〈https://ehoonline.biomedcentral.com/articles/10.1186/s40164-018-0097-6〉. 〈10.1186/s40164-018-0097-6〉
Experimental Hematology & Oncology, BMC, 2018, 7 (1), pp.5. ⟨10.1186/s40164-018-0097-6⟩
Experimental Hematology & Oncology
Experimental Hematology & Oncology, 2018, 7 (1), pp.5. 〈https://ehoonline.biomedcentral.com/articles/10.1186/s40164-018-0097-6〉. 〈10.1186/s40164-018-0097-6〉
Experimental Hematology & Oncology, BMC, 2018, 7 (1), pp.5. ⟨10.1186/s40164-018-0097-6⟩
Background Expression of SRY [sex-determining region Y]-box11 (SOX11) is specific to mantle cell lymphoma (MCL) and contributes, in conjunction with immunoglobulin variable heavy chain gene mutation status, to the identification of two forms of this
Autor:
Alizée Jenvrin, Francine Garnache-Ottou, Sophie Perrin, Fanny Angelot-Delettre, Philippe Saas, Elodie Bole-Richard, Adam Ceroi, Sabeha Biichle, Laure Philippe, Samuel Limat, Francis Bonnefoy, Eric Deconinck
Publikováno v:
Haematologica
Blastic plasmacytoid dendritic cell neoplasm is an aggressive hematologic malignancy with a poor prognosis. No consensus regarding optimal treatment modalities is currently available. Targeting the nuclear factor-kappa B pathway is considered a promi
Autor:
Philippe Saas, Frédéric Féger, Francis Bonnefoy, Julien Caumartin, Mohamad Mohty, Christophe Ferrand, Christophe Roumier, Maxime Fredon, Jean-René Pallandre, Marina Deschamps, Elizabeth Macintyre, Olivier Adotevi, Alizée Jenvrin, Yann Godet, Tony Petrella, Chloé Molimard, Maria Loustau, Frédéric Tsé, Francine Garnache-Ottou, Séverine Valmary-Degano, Etienne Daguindau, Kiave-Yune HoWangYin, François Anna, Florian Renosi, Eric Deconinck, Elodie Bole-Richard, Sabeha Biichle, Walid Warda, Jean-Marie Certoux, Pierre Langlade-Demoyen, Fanny Angelot-Delettre, Eolia Brissot, Maïder Pagadoy, Delphine Binda, Margaux Poussard
Publikováno v:
Leukemia. 34(12)
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is associated with a remarkably poor prognosis and with no treatment consensus. The identification of relevant therapeutic targets is challenging. Here, we investigated the immune functions, antile